Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03644966 · ClinicalTrials.gov registry record · NA
Probiotics and Multi-Drug Resistant Urinary Tract Infection
A NA study of Urinary Tract Infections and Antibiotic Resistant Infection, sponsored by Ochsner Health System.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03644966: Completed NA study of Urinary Tract Infections and Antibiotic Resistant Infection, sponsored by Ochsner Health System.
NCT03644966 is a NA study of Urinary Tract Infections and Antibiotic Resistant Infection that has completed, run by Ochsner Health System. The registered enrollment target is 25 participants, below the 458-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03644966, a NA study of Urinary Tract Infections and Antibiotic Resistant Infection, has completed, sponsored by Ochsner Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study is a single-site randomized, double blinded placebo-controlled in females with recurrent multi-drug resistant (MDR) urinary tract infections(UTI). Our study hypothesizes that a novel probiotic strain improves antibiotic sensitivity patterns in these former MDR UTIs.
Primary Outcome
The change in the quantity of antibiotics reported to be resistant per organism per culture per patient.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Antibiotics
- DIETARY_SUPPLEMENT Bifidobacterium infantis
Study Locations (1)
Louisiana
- Ochsner Health System - Jefferson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-07-05 |
| Est. Completion | 2022-12-15 |
| Phase | NA |
What the finished NCT03644966 record still lists
NCT03644966 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 458-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Urinary Tract Infections appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03644966 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT03644966 about?
NCT03644966 is a clinical study titled "Probiotics and Multi-Drug Resistant Urinary Tract Infection". This pilot study is a single-site randomized, double blinded placebo-controlled in females with recurrent multi-drug resistant (MDR) urinary tract infections(UTI). Our study hypothesizes that a novel probiotic strain improves antibiotic sensitivity patterns in these former MDR UTIs.
What is the current status of trial NCT03644966?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2018-07-05. Estimated completion is 2022-12-15.
What conditions does trial NCT03644966 study?
This clinical trial studies the following conditions: Urinary Tract Infections, Antibiotic Resistant Infection, Recurrent Uti.
What interventions are being tested in trial NCT03644966?
The interventions under investigation include: Placebo (OTHER), Antibiotics (DRUG), Bifidobacterium infantis (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03644966?
This trial is sponsored by Ochsner Health System, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03644966 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03644966's enrollment target sits among peer trials
25 31st of 34 higher than 4 of 34 other Urinary Tract Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Tract Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
RECRUITING · NA
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
-
Double Voiding and Post-transplant UTI
RECRUITING · NA
-
Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture
RECRUITING · NA
-
Effect of Standardization of Urine Collection Using PEEZY Device as Compared to Clean Peezy for DAB
ACTIVE NOT RECRUITING · NA
-
Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI